Circulating motilin, ghrelin, and GLP-1 and their correlations with gastric slow waves in patients with chronic kidney disease

What Was Tested

This controlled clinical trial paper looks at Ghrelin.

This study was designed 1) to study effects of HD on GI symptoms and gastric slow waves; and 2) to investigate possible roles of ghrelin and glucagon-like peptide-1 (GLP-1): the study recruited 13 healthy controls, 20 CKD patients without HD (CKD group), and 18 CKD patients with HD (HD group).

Why It Was Studied

Patients with chronic kidney disease (CKD) commonly complain upper gastrointestinal (GI) symptoms, especially anorexia.

Dyspeptic symptoms, autonomic functions, gastric slow waves, and plasma level of ghrelin and GLP-1 were analyzed.

Who Took Part

The study group was 20 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

What Was Measured

Patients with chronic kidney disease (CKD) commonly complain upper gastrointestinal (GI) symptoms, especially anorexia.

Dyspeptic symptoms, autonomic functions, gastric slow waves, and plasma level of ghrelin and GLP-1 were analyzed.

PubMed files the paper under topics including Gastrointestinal Hormones, Gastrointestinal Transit, Ghrelin, Glucagon-Like Peptide 1, Motilin, Myoelectric Complex, Migrating and Renal Dialysis.

The authors tagged it with the keywords chronic kidney disease, gastric slow wave, glucagon-like peptide-1 and hemodialysis.

What This Means in Plain Language

This is a controlled clinical trial of Ghrelin in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2017 (American journal of physiology. Regulatory, integrative and comparative physiology), a journal based in United States.

More context: the Ghrelin compound page, all human trials.